Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels

Abstract

BACKGROUND AND PURPOSELiver X receptor (LXR) agonists are atheroprotective but often induce hypertriglyceridaemia and liver steatosis. We investigated the effect of a novel high-affinity LXR activator, AZ876, on plasma lipids, inflammation and atherosclerosis, and compared the effects with another LXR agonist, GW3965. ) for 20 weeks. Total cholesterol and triglyceride levels were measured using commercial kits. Plasma cytokines were determined by using bead-based multiplex suspension array kits with the Luminex technology. Atherosclerosis was assessed histochemically and lesion composition was assessed by immunohistochemical methods. EXPERIMENTAL APPROACHAPOE KEY RESULTSLow-dose AZ876 had no effect on plasma or liver lipids, whereas high-dose AZ876 increased plasma triglycerides (+110%) and reduced cholesterol (-16%) compared with controls. GW3965 increased plasma triglycerides (+70%). Low-dose AZ876 reduced lesion area (-47%); and high-dose AZ876 strongly decreased lesion area (-91%), lesion number (-59%) and severity. In either dose, AZ876 did not affect lesion composition. GW3965 reduced atherosclerosis and collagen content of lesions (-23%; P < 0.01). High-dose AZ876 and GW3965, but not low-dose AZ876, reduced inflammation as reflected by lower cytokine levels and vessel wall activation. CONCLUSIONS AND IMPLICATIONSWe have identified a novel LXR agonist that when given in a low dose inhibits the progression of atherosclerosis without inducing anti-inflammatory effects, liver steatosis or hypertriglyceridaemia. Therefore, the primary protective action of a low-dose AZ876 is likely to be an increased reverse cholesterol transport. Abbreviations

Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men

“…Sitosterol and campesterol were extracted from plasma and analyzed by gas chromatography (GC)/MS (22). 7␣-hydroxy-4-cholesten-3-one (C4) was extracted from plasma and analyzed using liquid chromatography/MS/MS (23).…”

LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver

“…Because of the double-edged role of LXRa in the vascular and hepatic systems, only selective agonists or antagonists of this nuclear receptor have the potential for development as therapeutics. Recent studies have suggested that selective regulation of LXRa in target tissues may be applied to the treatment of many diseases, including metabolic syndromes [4,5].…”

Re-adopting classical nuclear receptors by cholesterol metabolites

“…LXRα is primarily expressed in the liver, intestine, adipose tissue, and macrophages, whereas LXRβ is expressed ubiquitously (43). Similar to ER, LXR activation reduces the development of atherosclerosis despite modest changes in plasma lipoprotein levels (44), suggesting that the underlying mechanism(s) may involve direct effects on vascular cell functions. Oxysterols such as 22(R)-hydroxycholesterol and 24(S)-hydroxycholesterol are major endogenous LXR ligands.…”